A multidisciplinary approach for COVID-19-associated myocarditis resulted in 0 deaths or malignant arrhythmias at 6 months, though 29% of patients were screened for heart transplantation.
Cohort (n=7)
A multidisciplinary approach to COVID-19-associated myocarditis resulted in no deaths or malignant arrhythmias at 6 months, though a significant proportion required advanced therapies such as hemodynamic support or transplant screening.
BACKGROUND: Myocarditis lacks systematic characterization in COVID-19 patients. METHODS: We enrolled consecutive patients with newly diagnosed myocarditis in the context of COVID-19 infection. Diagnostic and treatment strategies were driven by a dedicated multidisciplinary disease unit for myocarditis. Multimodal outcomes were assessed during prospective follow-up. RESULTS: = 3). Hemodynamic support was needed for four unstable patients (57%), whereas a cardiac device implant was chosen in two of four cases showing ventricular arrhythmias. Medical treatment included immunosuppression (43%) and biological therapy (29%). By the 6-month median follow-up, no patient died or experienced malignant arrhythmias. However, two cases (29%) were screened for heart transplantation. CONCLUSIONS: Myocarditis associated with acute COVID-19 infection is a spectrum of clinical manifestations and underlying etiologies. A multidisciplinary approach is the cornerstone for tailored management.
Peretto et al. (Tue,) conducted a cohort in COVID-19-Associated Myocarditis (n=7). Multidisciplinary disease unit management was evaluated on Death or malignant arrhythmias. A multidisciplinary approach for COVID-19-associated myocarditis resulted in 0 deaths or malignant arrhythmias at 6 months, though 29% of patients were screened for heart transplantation.